Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Homologous recombination deficiency and PARP inhibitors in therapeutics].
Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M. Salaün H, et al. Among authors: saint ghislain m. Bull Cancer. 2022 Jan;109(1):76-82. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17. Bull Cancer. 2022. PMID: 34799081 Review. French.
Adverse events of targeted therapies approved for women's cancers.
Saint-Ghislain M, Levenbruck C, Bellesoeur A. Saint-Ghislain M, et al. Int J Womens Dermatol. 2021 Oct 27;7(5Part A):552-559. doi: 10.1016/j.ijwd.2021.10.006. eCollection 2021 Dec. Int J Womens Dermatol. 2021. PMID: 35024412 Free PMC article. Review.
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.
Saint-Ghislain M, Derrien AC, Geoffrois L, Gastaud L, Lesimple T, Negrier S, Penel N, Kurtz JE, Le Corre Y, Dutriaux C, Gardrat S, Barnhill R, Matet A, Cassoux N, Houy A, Ramtohul T, Servois V, Mariani P, Piperno-Neumann S, Stern MH, Rodrigues M. Saint-Ghislain M, et al. Eur J Cancer. 2022 Sep;173:105-112. doi: 10.1016/j.ejca.2022.06.033. Epub 2022 Jul 19. Eur J Cancer. 2022. PMID: 35863105
Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma.
Champiat S, Salaün H, Lucibello F, Scoazec JY, Besse B, Lalanne AI, Rouleau E, Metzger N, Saint-Ghislain M, Ryckewaert T, Gardrat S, Barnhill R, Cassoux N, Stern MH, Lantz O, de Koning L, Marabelle A, Rodrigues M. Champiat S, et al. Among authors: saint ghislain m. JCO Precis Oncol. 2023 May;7:e2200363. doi: 10.1200/PO.22.00363. JCO Precis Oncol. 2023. PMID: 37224427 No abstract available.
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
Aldea M, Lam L, Orillard E, Llacer Perez C, Saint-Ghislain M, Gravis G, Fléchon A, Roubaud G, Barthelemy P, Ricci F, Priou F, Neviere Z, Beaufils M, Laguerre B, Hardy AC, Helissey C, Ratta R, Borchiellini D, Pobel C, Joly F, Castro E, Thiery-Vuillemin A, Baciarello G, Fizazi K. Aldea M, et al. Among authors: saint ghislain m. Eur J Cancer. 2021 Dec;159:87-97. doi: 10.1016/j.ejca.2021.09.029. Epub 2021 Nov 2. Eur J Cancer. 2021. PMID: 34742160
Lack of evidence for CDK12 as an ovarian cancer predisposing gene.
Eeckhoutte A, Saint-Ghislain M, Reverdy M, Raynal V, Baulande S, Bataillon G, Golmard L, Stoppa-Lyonnet D, Popova T, Houdayer C, Manié E, Stern MH. Eeckhoutte A, et al. Among authors: saint ghislain m. Fam Cancer. 2020 Jul;19(3):203-209. doi: 10.1007/s10689-020-00169-2. Fam Cancer. 2020. PMID: 32172432 Free article.
Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial.
Basse C, Morel C, Callens C, Pierron G, Servois V, Vincent-Salomon A, Jobard A, Alt M, Ricci F, Loirat D, Sablin MP, Bretagne M, Saint-Ghislain M, Hescot S, Gonçalves A, Tredan O, Dubot C, Gavoille C, Delord JP, Campone M, Isambert N, Belin L, Bieche I, Kamal M, Le Tourneau C. Basse C, et al. Among authors: saint ghislain m. JCO Precis Oncol. 2018 Oct 19;2:PO.18.00048. doi: 10.1200/PO.18.00048. eCollection 2018. JCO Precis Oncol. 2018. PMID: 32914004 Free PMC article.
17 results